https://www.selleckchem.com/pr....oducts/iacs-010759-i
ation. This article is protected by copyright. All rights reserved.The farnesoid X receptor (FXR)-fibroblast growth factor 19 (FGF19) axis has provided promising therapeutic targets for nonalcoholic steatohepatitis (NASH), with obeticholic acid (OCA), the first-in-class FXR agonist, showing fibrosis improvement in two human trials.(1,2) FXR regulates bile acid, lipid, and glucose metabolism by controlling a broad transcriptional repertoire in the intestine and the liver. FGF19, the most prominent FXR target gene in the in
Like
Comment
Share
